You are now leaving the ViiV Healthcare website and being re-directed to an external website
Explore ViiV Healthcare
ViiV Healthcare @ AIDS 2018
Find out more about our key events and activities during the 22nd International AIDS Conference in Amsterdam.
GEMINI 1 & 2 studies meet primary endpoint, showing two-drug regimen to be effective across high and low viral loads
ViiV Healthcare’s Global Lead HIV Remission/Cure, Jim Demarest explores the topic of cure and remission in HIV.
100-week results from the SWORD phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three or four-drug antiretroviral regimen to a 2-drug regimen of dolutegravir. and rilpivirine.
ViiV Exchange - resources for HIV specialists and healthcare professionals
ViiV Healthcare’s broad portfolio consists of 12 antiretroviral medicines, offering a wide range of therapeutic options for people living with HIV.
ViiV Healthcare’s pipeline includes medicines for the treatment and prevention of HIV to lessen the burden of the disease globally.
The ViiV Healthcare Clinical Study Register supplements existing medical knowledge with easily-accessible data from our sponsored clinical studies.
At ViiV Healthcare our scientists are dedicated to finding new medicines to limit the impact of HIV through both prevention and treatment.
©2018 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare UK Limited. Registered in England and Wales No. 06990358. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
Connect with us